SOURCE: The Trout Group LLC

The Trout Group LLC

December 08, 2015 11:16 ET

The Trout Group to Host a "Trout Talk" Key Opinion Leader Meeting and Live Webcast on December 11 in New York City

Christopher Heery, MD, Director of the Clinical Trials Group of Tumor Immunology and Biology at the National Cancer Institute to Present His Work on Cancer Vaccines in New York City

NEW YORK, NY--(Marketwired - December 08, 2015) - The Trout Group, the leading global investor relations and strategic advisory firm servicing the life sciences industry, will host a KOL lunch and live webcast on December 11, at 12 pm ET in New York City. This event marks the 26th presentation in Trout's Cancer Immunotherapy "Trout Talks" series. The live webcast of the event will be available at trouttalks.troutgroup.com.

The invited speaker for this event is Dr. Christopher Heery, MD, Director of the Clinical Trials Group of Tumor Immunology and Biology at the National Cancer Institute, and an expert in the field of cancer vaccines. In addition to presenting his own work (i.e.: PANVAC), Dr. Heery will be taking any and all questions regarding cancer vaccine research and development.

Heery was trained at the National Cancer Institute with the Laboratory of Tumor Immunology and Biology and mentored by Dr. Jeffrey Schlom, Dr. James Gulley, and Dr. Ravi Madan. His research interests include cancer immunotherapy, cancer vaccines, and the identification of meaningful surrogates for patient outcomes in the setting of immunotherapy.

The talk, moderated by Trout Group scientific advisor Neil Canavan, will consist of a 45 minutes presentation by Dr. Heery, followed by 15 minutes of questions from the audience. Questions from webcast participants should be sent to ncanavan@troutgroup.com. The next Trout Talk in our Cancer Immunotherapy series is scheduled for December 18, 2015 in New York City and will feature the work of Dr. Dario Vignali. Investors wishing to attend these or the future events should RSVP to ptill@troutgroup.com.

Please join Trout at our Annual 1x1 Management Access Event in San Francisco, January 11-14, 2016: troutsf2016.troutgroup.com.

The Trout Group is a co-sponsor of the 'Even More of What's Hot in Immuno-Oncology Licensing" web panel on December 10, 2015. Learn from industry experts by registering here.

Recent publications by Dr. Heery:

The impact of leukapheresis on immune-cell number and function in patients with advanced cancer.
Gulley JL, Marté J, Heery CR, Madan RA, Steinberg SM, Leitman SF, Tsang KY, Schlom J.
Springer. 2015 Nov; 64(11):1429-35.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Heery CR, Ibrahim NK Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL
JAMA Oncology. 2015 Nov 1; 1(8):1087-95.

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL.
AACRJournals. 2015 Nov; 3(11):1248-56.

Current Clinical Trial by Dr. Heery as Principal Investigator:

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

About The Trout Group:
Since 1996, Trout has been the leading strategic partner to the life sciences industry, connecting companies, investors and the most exciting innovations in the sector. With a unique suite of services in investor relations, communications and financial advisory, Trout is at the intersection through which scientific advances and its network of powerful relationships can meet to create long term value for stakeholders.

Contact Information